Trial Profile
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BCX7353 as a Preventative Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms APeX-1
- Sponsors BioCryst Pharmaceuticals
- 05 Nov 2018 According to BioCryst media release, the data will be presented at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2018.
- 26 Jul 2018 Results published in the New England Journal of Medicine
- 25 Jul 2018 According to a BioCryst Pharmaceuticals media release, the company announced that data from this trial are published online in the July 26th issue of The New England Journal of Medicine.